While these data make a compelling case for targeting the PI3K pathway as a therapeutic strategy for Ph+ ALL, its potential pathophysiologic role and value as a therapeutic target in BCR-ABL negative B-lineage ALL remain largely unexplored. This evidence concerns the gene PIK3CA and acute lymphoblastic leukemia.